Immunogenicity of a Recombinant Pre-S2-containing Hepatitis B Vaccine Versus Plasma-derived Vaccine Administered As a Booster

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1994 Mar 1

PMID 8050433

Citations 2

Authors

B Bucher

P Francioli

B Geudelin

B Fritzell

D Lavanchy

P C Frei

Affiliations

Soon will be listed here.

Abstract

GenHevac B Pasteur is a recombinant hepatitis B vaccine derived from a mammalian cell line and containing HBs as well as pre-S2 antigens. Its immunogenicity was compared to that of the plasma-derived vaccine Hevac B Pasteur in a population primovaccinated 5.5 years earlier with four injections of the same plasma vaccine. The booster injection with either GenHevac or Hevac was administered to 295 subjects with residual anti-HBs titres below 500 IU/l (group 1: 0-9; group 2: 10-99; group 3: 100-499 IU/l). After four weeks, GenHevac had induced higher anti-HBs responses than Hevac in all groups, particularly among the low responders of group 1. Response to the vaccine occurred earlier with GenHevac. Mean anti-pre-S2 production was moderate in all groups for both vaccines (GenHevac: 60 IU/l; Hevac: 31 IU/l) and was not found in the 32 subjects who produced less than 100 IU/l anti-HBs. The results of the present study indicate that GenHevac is at least as immunogenic as Hevac.

Citing Articles

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Kushnir N, Streatfield S, Yusibov V Vaccine. 2012; 31(1):58-83.

PMID: 23142589 PMC: 7115575. DOI: 10.1016/j.vaccine.2012.10.083.

Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran.

Yazdanpanah B, Safari M, Yazdanpanah S Hepat Mon. 2012; 10(1):17-21.

PMID: 22308120 PMC: 3270339.

References

Milich D, Thornton G, Neurath A, Kent S, Michel M, Tiollais P . Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985; 228(4704):1195-9. DOI: 10.1126/science.2408336. View

Heermann K, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich W . Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol. 1984; 52(2):396-402. PMC: 254539. DOI: 10.1128/JVI.52.2.396-402.1984. View

Ibarra M, Mora I, Bartolome J, Porres J, Carreno V . Detection of proteins encoded by the pre-S region of hepatitis B virus in the sera of HBsAg carriers: relation to viral replication. Liver. 1989; 9(3):153-8. DOI: 10.1111/j.1600-0676.1989.tb00392.x. View

Miller R, Kaneko S, Chung C, Girones R, Purcell R . Compact organization of the hepatitis B virus genome. Hepatology. 1989; 9(2):322-7. DOI: 10.1002/hep.1840090226. View

Michel M, Pontisso P, Sobczak E, Malpiece Y, Streeck R, Tiollais P . Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci U S A. 1984; 81(24):7708-12. PMC: 392221. DOI: 10.1073/pnas.81.24.7708. View

Kurai K, Iino S, Koike K, Mitamura K, Endo Y, Oka H . Serum titers of pre-S(2) antigen in patients with acute and chronic type B hepatitis: relation to serum aminotransferase activity and other hepatitis B virus markers. Hepatology. 1989; 9(2):175-9. DOI: 10.1002/hep.1840090202. View

Charbit A, Sobczak E, Michel M, Molla A, Tiollais P, Hofnung M . Presentation of two epitopes of the preS2 region of hepatitis B virus on live recombinant bacteria. J Immunol. 1987; 139(5):1658-64. View

Hadziyannis S, Raimondo G, Papaioannou C, Anastassakos C, Wong D, Sninsky J . Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication. J Hepatol. 1987; 5(3):253-9. DOI: 10.1016/s0168-8278(87)80029-6. View

Ishihara K, Waters J, Pignatelli M, Thomas H . Characterisation of the polymerised and monomeric human serum albumin binding sites on hepatitis B surface antigen. J Med Virol. 1987; 21(1):89-95. DOI: 10.1002/jmv.1890210112. View

10.

Zanetti A, Tanzi E, Mannucci P . Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs. J Med Virol. 1989; 28(3):156-8. DOI: 10.1002/jmv.1890280309. View

11.

Milich D, McLachlan A, Chisari F, Nakamura T, Thornton G . Two distinct but overlapping antibody binding sites in the pre-S(2) region of HBsAg localized within 11 continuous residues. J Immunol. 1986; 137(8):2703-10. View

12.

Machida A, Kishimoto S, Ohnuma H, Miyamoto H, Baba K, Oda K . A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology. 1983; 85(2):268-74. View

13.

Fujisawa Y, Kuroda S, van Eerd P, Schellekens H, Kakinuma A . Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine. 1990; 8(3):192-8. DOI: 10.1016/0264-410x(90)90044-m. View

14.

Milich D, McLachlan A, Chisari F, Thornton G . Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre-S(2) region synthetic peptide. J Exp Med. 1986; 164(2):532-47. PMC: 2188234. DOI: 10.1084/jem.164.2.532. View

15.

Lavanchy D, Fritzell B, Geudelin B, Peitrequin R, Frei P . Anti-pre-S2 antibody response in subjects vaccinated against hepatitis B and in naturally immunized subjects. Res Virol. 1991; 142(5):363-71. DOI: 10.1016/0923-2516(91)90003-l. View

16.

Thung S, Wang D, Fasy T, Hood A, Gerber M . Hepatitis B surface antigen binds to human serum albumin cross-linked by transglutaminase. Hepatology. 1989; 9(5):726-30. DOI: 10.1002/hep.1840090512. View

17.

Alberti A, Cavalletto D, Pontisso P, Chemello L, Tagariello G, Belussi F . Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet. 1988; 1(8600):1421-4. DOI: 10.1016/s0140-6736(88)92237-4. View

18.

Coursaget P, Adamowicz P, Bourdil C, Yvonnet B, Buisson Y, Barres J . Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization. Vaccine. 1988; 6(4):357-61. DOI: 10.1016/0264-410x(88)90183-1. View

19.

Jilg W, Schmidt M, Zachoval R, Deinhardt F . [Persistence of antibodies against hepatitis B surface antigens after vaccination against hepatitis B]. Dtsch Med Wochenschr. 1985; 110(6):205-9. DOI: 10.1055/s-2008-1068799. View

20.

Rossier P, Peitrequin R, Frei P . [The hepatitis B vaccination campaign carried out from 1982 to 1984 using the Hevac B Pasteur vaccine among 6162 employees of Vaud hospitals]. Schweiz Med Wochenschr. 1987; 117(17):629-37. View